Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | KB-0742 |
Synonyms | |
Therapy Description |
KB-0742 is a CDK9 inhibitor, which may result in reduced Cdk9-mediated transcriptional activity, apoptotic induction, and inhibition of tumor growth (PMID: 33086052). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KB-0742 | KB0742|KB 0742 | CDK9 Inhibitor 21 | KB-0742 is a CDK9 inhibitor, which may result in reduced Cdk9-mediated transcriptional activity, apoptotic induction, and inhibition of tumor growth (PMID: 33086052). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04718675 | Phase I | KB-0742 | A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma | Active, not recruiting | USA | GBR | ESP | 0 |